• Single IV cycle of PsiOxus’ T-SIGn vector enabled an otherwise non-effective dose of CAR-T cell therapy to clear primary and metastatic tumors in vivo • Reprogramming of the tumor… read more →
PsiOxus announced, today, an updated agreement to advance its clinical collaboration with Bristol Myers Squibb to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination… read more →
PsiOxus Therapeutics Ltd congratulates its very own Priya Mande, COO, as well as all the other award winners who have been recognised by The Healthcare Technology Report in their Top… read more →
In her capacity as Chair of the UK Vaccine Taskforce, Kate Bingham announced the appointment of Priya Mande to the UK Vaccine Taskforce. Priya will be working with Kate to… read more →
PsiOxus, the gene therapy for cancer company, today announced that it has started a clinical trial with NG-641, a four transgene tumor-microenvironment modifying cancer gene therapy. This is the first… read more →
March 13, 2019 – OXFORD, UK – PsiOxus Therapeutics Ltd. (PsiOxus), the gene therapy for cancer company, today announced that it has started dosing NG-350A, an antibody based cancer gene… read more →
Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the… read more →
A fantastic article in Endpoint News about the collaboration between PsiOxus and the Parker Institute for Cancer Immunotherapy.
Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at… read more →
December 12, 2017 –OXFORD, UK – PsiOxus Therapeutics, Ltd. (PsiOxus) today announced that the Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors, has… read more →
